Real-World Patterns of Utilization of Lenalidomide-based Triplet Regimens in FIrst RElapsed Multiple Myeloma Patients: Evidence From Medical Record Review

Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse

NCT01217203 ·Status: COMPLETED ·Phase: PHASE1

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

NCT02252172 ·Status: COMPLETED ·Phase: PHASE3

RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma

NCT03908138 ·Status: UNKNOWN ·Phase: PHASE4

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

NCT03617731 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

NCT03104842 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

NCT03111992 ·Status: COMPLETED ·Phase: PHASE1

Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe

NCT03091127 ·Status: COMPLETED

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

NCT01080391 ·Status: COMPLETED ·Phase: PHASE3

A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

NCT00405756 ·Status: COMPLETED ·Phase: PHASE3

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

NCT02874742 ·Status: COMPLETED ·Phase: PHASE2

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

NCT01237249 ·Status: COMPLETED ·Phase: PHASE2

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

NCT03601078 ·Status: COMPLETED ·Phase: PHASE2

Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide

NCT03184194 ·Status: COMPLETED ·Phase: PHASE2

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

NCT04497961 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT03859427 ·Status: COMPLETED ·Phase: PHASE3

A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma

NCT06497738 ·Status: RECRUITING

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

NCT05849610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma

NCT00306813 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

NCT03710603 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

NCT06353022 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

NCT01592370 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

RMPT for Relapsed/Refractory Multiple Myeloma

NCT00961467 ·Status: COMPLETED ·Phase: PHASE2

RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

NCT00729638 ·Status: COMPLETED ·Phase: PHASE1

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

NCT04140162 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

NCT03433001 ·Status: COMPLETED